Abstract
Background
Hepatorenal syndrome (HRS) is a common complication in patients with cirrhosis or fulminant liver failure. We systematically reviewed the benefits and harms of using terlipressin, a novel vasoconstricting agent in patients with HRS.
Methods
We searched MEDLINE, SCOPUS, and conference proceedings for relevant trials of terlipressin. Results were summarized using the random-effects model.
Results
Eight trials (320 participants) were included. When compared with placebo, terlipressin-treated patients had higher HRS reversal (odds ratio [OR] 7.47, 95% confidence interval [CI] 3.17–17.59), mean arterial pressure (weighted mean difference [WMD] 11.26 mmHg, 95% CI 1.52–21), and urine output. There was a significant increase in ischemic adverse events with terlipressin when compared to placebo. There was mild-to-moderate heterogeneity in these analyses. There was no significant difference between terlipressin and noradrenaline in HRS reversal (OR 1.23, 95% CI, 0.43–3.54), mean arterial pressure, and urine output. Side-effect profile did not differ between terlipressin and noradrenaline.
Conclusion
Terlipressin improves HRS reversal and other surrogate outcome measures compared with placebo, but no significant differences for these outcomes were noted when comparing terlipressin and noradrenaline. Terlipressin is a potential therapeutic option for HRS, but larger trials comparing terlipressin to other widely used vasoconstrictors are warranted.
Similar content being viewed by others
References
Koppel MH, Coburn JW, Mims MM et al (1969) Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 280:1367–1371
Epstein M, Berk DP, Hollenberg NK et al (1970) Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49:175–185
Krasko A, Deshpande K, Bonvino S (2003) Liver failure, transplantation, and critical care. Crit Care Clin 19:155–183
Ginès A, Escorsell A, Ginès P et al (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105:229–236
http://www.icascites.org/guidelines.htm. Last accessed February 12, 2010
Lafayette RA, Paré G, Schmid CH et al (1997) Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 48:159–164
Restuccia T, Ortega R, Guevara M et al (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 40:140–146
Alessandria C, Ozdogan O, Guevara M et al (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41:1282–1289
Marik PE, Wood K, Starzl TE (2006) The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 21:478–482
Schrier RW, Arroyo V, Bernardi M et al (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8:1151–1157
Moreau R, Lebrec D (2008) Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors. Nephron Physiol 109(4):73–79
Garcia-Tsao G, Parikh CR, Viola A (2008) Acute kidney injury in cirrhosis. Hepatology 48:2064–2077
Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA (2007) Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 52:742–748
Kalambokis G, Economou M, Fotopoulos A et al (2005) The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 100:879–885
Sharma P, Kumar A, Shrama BC, Sarin SK (2008) An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103:1689–1697
Sanyal AJ, Boyer T, Garcia-Tsao G et al (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134:1360–1368
Martín-Llahí M, Pépin MN, Guevara M et al (2008) Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134:1352–1359
Alessandria C, Ottobrelli A, Debernardi-Venon W et al (2007) Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 47:499–505
Testro AG, Wongseelashote S, Angus PW, Gow PJ (2008) Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 23(10):153–158
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18:152–156
Neri S, Pulvirenti D, Malaguarnera M et al (2008) Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 53:830–835
Hadengue A, Gadano A, Moreau R et al (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29:565–570
Yang YZ, Dan ZL, Liu NZ, Liu M et al (2001) Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. J Inter Intensive Med 7:123–125
Gluud LL, Kjaer MS, Christensen E (2006) Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 4:CD005162
Fabrizi F, Dixit V, Martin P (2006) Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 24:935–944
Fabrizi F, Dixit V, Messa P, Martin P (2009) Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials. Int J Artif Organs 32:133–140
Acknowledgment
We would like to thank the authors of the included studies who provided additional study details and Ms. Sandra Bronoff, Cleveland Clinic for her editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dobre, M., Demirjian, S., Sehgal, A.R. et al. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 43, 175–184 (2011). https://doi.org/10.1007/s11255-010-9725-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-010-9725-8